Analyst Alec Stranahan of Bank of America Securities maintained a Buy rating on RegenXBio (RGNX – Research Report), retaining the price target of $22.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alec Stranahan has given his Buy rating due to a combination of factors that highlight RegenXBio’s strategic approach and promising outlook. The company has implemented an immune suppression regimen from the outset, which may contribute to the superior safety profile of RGX-202, especially in comparison to competitors like Sarepta’s Elevidys. This proactive measure has resulted in no reported cases of drug-induced liver injury, a significant concern in the field.
Moreover, RegenXBio’s RGX-202 is designed with both safety and efficacy in mind, utilizing advanced vector design and manufacturing techniques to minimize immune response. The company’s interactions with regulatory agencies have been positive, and there is a clear path to market with expected milestones such as full enrollment by 2025 and a potential Biologics License Application filing by mid-2026. These factors, combined with an improving view of the addressable market, support the Buy rating and the price objective of $22.